Biomarkers in hepatocellular carcinoma: diagnosis, prognosis and treatment response assessment

F Piñero, M Dirchwolf, MG Pessôa - Cells, 2020 - mdpi.com
Hepatocellular carcinoma (HCC) is one of the main cancer-related causes of death
worldwide. Thus, there is a constant search for improvement in screening, diagnosis, and …

Hepatocellular carcinoma: current management and perspectives for the future

NN Rahbari, A Mehrabi, NM Mollberg, SA Müller… - Annals of …, 2011 - journals.lww.com
Objective: To review the literature on current management of hepatocellular carcinoma
(HCC). Background: Hepatocellular carcinoma represents one of the most common …

Impact of pretransplant bridging locoregional therapy for patients with hepatocellular carcinoma within Milan criteria undergoing liver transplantation: analysis of 3601 …

VG Agopian, MP Harlander-Locke, RM Ruiz… - Annals of …, 2017 - journals.lww.com
Objective: To evaluate the effect of pretransplant bridging locoregional therapy (LRT) on
hepatocellular carcinoma (HCC) recurrence and survival after liver transplantation (LT) in …

The treatment of intermediate stage tumours beyond TACE: From surgery to systemic therapy

PR Galle, F Tovoli, F Foerster, MA Wörns… - Journal of …, 2017 - Elsevier
Treatment of hepatocellular carcinoma (HCC) is dependent on the stage of the disease.
Intermediate stage HCC encompasses the largest subgroup of patients with the disease …

Response to terlipressin and albumin is associated with improved liver transplant outcomes in patients with hepatorenal syndrome

S Piano, C Gambino, E Vettore, V Calvino… - …, 2021 - Wiley Online Library
Background and Aims Although terlipressin and albumin are effective at treating acute
kidney injury‐hepatorenal syndrome (AKI‐HRS), liver transplantation (LT) is the best …

[HTML][HTML] A multistep, consensus-based approach to organ allocation in liver transplantation: toward a “blended principle model”

U Cillo, P Burra, V Mazzaferro, L Belli, AD Pinna… - American Journal of …, 2015 - Elsevier
Since Italian liver allocation policy was last revised (in 2012), relevant critical issues and
conceptual advances have emerged, calling for significant improvements. We report the …

[HTML][HTML] Hepatocellular carcinoma locoregional therapies for patients in the waiting list. Impact on transplantability and recurrence rate

M Cescon, A Cucchetti, M Ravaioli, AD Pinna - Journal of hepatology, 2013 - Elsevier
The practice of treating candidates for liver transplantation (LT) for hepatocellular carcinoma
(HCC), with locoregional therapies, is common in most transplant centers. However, for T1 …

[HTML][HTML] Prognostic factors for hepatocellular carcinoma recurrence

A Colecchia, R Schiumerini, A Cucchetti… - World journal of …, 2014 - ncbi.nlm.nih.gov
The recurrence of hepatocellular carcinoma, the sixth most common neoplasm and the third
leading cause of cancer-related mortality worldwide, represents an important clinical …

[HTML][HTML] Position paper of the Italian Association for the Study of the Liver (AISF): the multidisciplinary clinical approach to hepatocellular carcinoma

L Bolondi, U Cillo, M Colombo, A Craxì… - Digestive and Liver …, 2013 - Elsevier
Patients with hepatocellular carcinoma should be managed with a multidisciplinary
approach framed in a network where all the diagnostic techniques and therapeutic …

Complete pathologic response to pretransplant locoregional therapy for hepatocellular carcinoma defines cancer cure after liver transplantation: analysis of 501 …

VG Agopian, MM Morshedi, J McWilliams… - Annals of …, 2015 - journals.lww.com
Objectives: To evaluate the rate, effect, and predictive factors of a complete pathologic
response (cPR) in patients with hepatocellular carcinoma (HCC) undergoing locoregional …